首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1911686

乾眼症市場規模、佔有率和成長分析（按產品、劑型、通路和地區分類）－2026-2033年產業預測

Dry Eye Syndrome Market Size, Share, and Growth Analysis, By Product (Over the Counter Artificial Tears & Lubricants, Prescription Drugs), By Dosage Form, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月01日 | 出版商:

SkyQuest | 英文 188 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球乾眼症市場規模將達到 83.1 億美元，到 2025 年將達到 89.6 億美元，到 2033 年將達到 164.7 億美元，預測期（2026-2033 年）的複合年成長率為 7.9%。

全球乾眼症 (DES) 市場正經歷顯著成長，這主要得益於治療方案從非處方潤滑劑轉向潛在發炎機制的處方藥。處方藥物技術的進步主要集中在緩解疾病療法上，旨在解決瞼板腺功能障礙、眼表發炎和淚膜不穩定等問題。乾眼症盛行率的不斷上升，尤其是在老年人和合併其他疾病的人群中，進一步推動了市場擴張。臨床上顯著的乾眼症影響著超過 3,400 萬美國，在歐洲和東亞的發病率也在上升，因此乾眼症的治療格局正在不斷發展，以滿足老齡化人口的需求。慢性疾病和體內化學物質的改變加劇了這種疾病的複雜性。

全球乾眼症市場促進因素

全球乾眼症市場的主要驅動力是人口老化和乾眼症狀盛行率的上升。隨著需要持續照護的老年人數量激增，處方藥和非處方藥的需求也相應成長。此外，長時間使用電子螢幕可能會導致潤滑劑銷售在短期內激增，並推動人們對治療方案的長期關注。北美市場尤為突出，有望實現顯著的財務成長。這種充滿活力的市場環境必將為創新治療方法和診斷服務在市場中永續發展提供機會。

全球乾眼症市場限制因素

全球乾眼症市場面臨嚴峻挑戰，原因在於相當一部分患者未被診斷和治療。許多患者選擇自行服用非處方藥，而非尋求專業醫療諮詢。這一趨勢限制了製藥公司開發用於有效治療乾眼症的藥物的收入成長潛力。因此，只有部分患者可能最終會轉而使用處方藥，這將進一步阻礙市場擴張，尤其是對於先進且昂貴的治療方案。因此，只要人們對乾眼症的認知和診斷率仍然較低，該市場就可能無法充分發揮其潛力。

全球乾眼症市場趨勢

全球乾眼症市場正經歷著一場意義深遠的變革時期，治療重點已從單純緩解症狀轉向採用創新處方療法解決根本病因。臨床醫師正逐漸拋棄傳統的非處方藥，轉而選擇針對發炎路徑並增強淚膜穩定性的藥物。這一趨勢的驅動力源於新藥的湧現以及旨在評估其長期療效的臨床試驗的發展。此外，強化高價值的臨床服務、制定專科處方集集以及積極的研發活動（包括胜肽、神經興奮劑和緩釋製劑等新型治療方法）在重塑乾眼症治療模式方面發揮關鍵作用。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

AbbVie Inc.（United States）
Bausch+Lomb（Canada）
Novartis AG（Switzerland）
Johnson & Johnson Services, Inc.（United States）
Santen Pharmaceutical Co., Ltd.（Japan）
Alcon Inc.（Switzerland）
Sun Pharmaceutical Industries Ltd.（India）
Otsuka Pharmaceutical Co., Ltd.（Japan）
Viatris Inc.（United States）
Kala Pharmaceuticals, Inc.（United States）
Novaliq GmbH（Germany）
AFT Pharmaceuticals（New Zealand）
Aldeyra Therapeutics（United States）
OASIS Medical（United States）
Akorn Operating Company LLC（United States）
Nicox SA（France）
Ocular Therapeutix, Inc.（United States）
Mitotech SA（Luxembourg）
Tarsus Pharmaceuticals, Inc.（United States）
Stuart Therapeutics（United States）

結論與建議

簡介目錄

Product Code: SQMIG35G2356

Global Dry Eye Syndrome Market size was valued at USD 8.31 Billion in 2024 and is poised to grow from USD 8.96 Billion in 2025 to USD 16.47 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026-2033).

The global dry eye syndrome (DES) market is experiencing significant growth driven by a shift from over-the-counter lubricants to prescription therapies targeting underlying inflammatory mechanisms. Advancements in prescription drug technologies focus on disease-modifying treatments that address meibomian gland dysfunction, ocular surface inflammation, and tear-film instability. The escalating prevalence of dry eye disease, particularly among older populations and those with associated health conditions, further propels market expansion. With over 34 million Americans affected by clinically significant dry eye, and a rising incidence observed in Europe and East Asia, the landscape of dry eye treatment is evolving to meet the demands of an aging demographic. Long-standing diseases and chemical changes in the body contribute to the increasing complexity of this condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Dry Eye Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Dry Eye Syndrome Market Segments Analysis

Global Dry Eye Syndrome Market is segmented by Product, Dosage Form, Distribution Channel and region. Based on Product, the market is segmented into Over the Counter (OTC) Artificial Tears & Lubricants, Prescription Drugs, Punctual Plugs, Nutraceuticals & Omega-3 Supplements and Autologous Serum & Blood-Derived Tear Substitutes. Based on Dosage Form, the market is segmented into Eye Drops and Ointments & Gels. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Independent Pharmacies & Drug Stores and Online Pharmacies & E-Commerce Portals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Dry Eye Syndrome Market

The Global Dry Eye Syndrome market is primarily fueled by the increasing aging population alongside a growing prevalence of dry eye conditions. As the number of older individuals requiring ongoing care continues to escalate, there is a corresponding rise in the demand for both prescription and over-the-counter treatments. Additionally, prolonged screen time contributes to short-term spikes in lubricant sales and may foster long-term interest in therapeutic solutions. North America stands out as a key market, with significant financial growth anticipated. This dynamic landscape ensures that innovative treatments and diagnostic services will consistently have opportunities to thrive within the market.

Restraints in the Global Dry Eye Syndrome Market

The Global Dry Eye Syndrome market faces significant challenges due to a considerable portion of patients remaining undiagnosed and untreated. Many individuals opt for self-treatment using over-the-counter eye drops instead of seeking professional medical advice. This behavior limits the potential revenue growth for pharmaceutical companies developing treatments aimed at managing the condition effectively. As a result, there is a limited patient base transitioning to prescription medications, which can further hinder market expansion, especially for more advanced and costly treatment options. Consequently, the market may struggle to achieve its full potential as awareness and diagnosis of dry eye syndrome remain inadequate.

Market Trends of the Global Dry Eye Syndrome Market

The global dry eye syndrome market is undergoing a significant transformation as the focus shifts from merely alleviating symptoms to addressing the underlying disease processes through innovative prescription treatments. Clinicians are increasingly prioritizing medications that target inflammatory pathways and enhance tear film stability, moving away from traditional over-the-counter solutions. This trend is bolstered by the emergence of new medications and the initiation of clinical trials aimed at long-term efficacious outcomes. Enhanced offerings in high-value clinics, specialty formularies, and robust research and development efforts-including new classes of therapies such as peptides, neurostimulants, and sustained-release formulations-are playing a crucial role in reshaping treatment paradigms for dry eye syndrome.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Dry Eye Syndrome Market Size by Product & CAGR (2026-2033)

Market Overview
Over the Counter (OTC) Artificial Tears & Lubricants
Prescription Drugs
Punctual Plugs
Nutraceuticals & Omega-3 Supplements
Autologous Serum & Blood-Derived Tear Substitutes

Global Dry Eye Syndrome Market Size by Dosage Form & CAGR (2026-2033)

Market Overview
Eye Drops
Ointments & Gels

Global Dry Eye Syndrome Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Independent Pharmacies & Drug Stores
Online Pharmacies & E-Commerce Portals

Global Dry Eye Syndrome Market Size & CAGR (2026-2033)

North America (Product, Dosage Form, Distribution Channel)
- US
- Canada
Europe (Product, Dosage Form, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Dosage Form, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Dosage Form, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Dosage Form, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch + Lomb (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alcon Inc. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kala Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novaliq GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AFT Pharmaceuticals (New Zealand)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aldeyra Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OASIS Medical (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Akorn Operating Company LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nicox S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocular Therapeutix, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mitotech S.A. (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tarsus Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stuart Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments